Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 17, 2009

Therapure Biopharma to Perform Fill/Finish of YM Biosciences’ Nimotuzumab

  • Therapure Biopharma has been contracted to provide fill-and-finish services for nimotuzumab, a humanized monoclonal antibody licensed to YM Biosciences' majority-owned Canadian subsidiary, CIMYM BioSciences, by the Centre of Molecular Immunology.

    Therapure will formulate and fill nimotuzumab into sterile vials in its aseptic GMP-certified and Health Canada licensed fill suite in Mississauga, Canada. The facility is built to FDA, EMEA, MHRA, and Health Canada standards. The final product will be utilized by YM BioSciences and its licensees, Daiichi Sankyo in Japan, Kuhnil in South Korea, and Oncoscience  in Europe for all activities and by Innogene Kalbiotech, YM's licensee in Southeast Asia, for global clinical trials.

    Nimotuzumab is currently being evaluated in 32 clinical studies worldwide in numerous indications, including multiple stages of non-small-cell lung cancer, pediatric and adult glioma, esophageal cancer, pancreatic cancer, gastric cancer, and head and neck cancer. Three Phase III trials and eight Phase II trials of those 32 are being conducted between YM and its four licensees.

    Nimotuzumab has been approved for marketing in 23 countries including Argentina, Brazil, China, India, Indonesia, and, most recently, Mexico.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »